穿孔性胃潰瘍:要關閉或修補 - 一個百年歷史的爭議
Khalid Mahmoud1, Mohamad K Abou Chaar1, Daniel Stephens1
1Surgery Research Office; Division of Trauma, Critical Care, and General Surgery, Department of Surgery, Mayo Clinic, Rochester, MN, United States.
概括
穿孔性胃潰瘍的縫合式關閉與與僅用貼片修復相比,較低的泄漏風險有關. 免疫抑制和乳酸盐水平升高也增加了泄漏的可能性.
科学领域:
- 胃肠病学 胃肠病学
- 手术创新 在外科创新.
- 临床结果研究研究
背景情况:
- 穿孔性胃潰瘍對外科手術提出了重大挑戰.
- 选择最佳的修复技术对于患者的治疗结果至关重要.
研究的目的:
- 为了比较不同外科手术技术的有效性进行穿孔性胃潰瘍修复.
- 为了确定与术后泄漏相关的因素.
主要方法:
- 对277名因穿孔性胃而接受手术的患者 (2004-2021) 的回顾性审查.
- 分析各种修复方法,包括关闭,补丁修复和胃切除术.
- 后勤回归用于识别泄漏的独立预测因素.
主要成果:
- 合式关闭与比只修补补丁更低的泄漏率有关.
- 随着钉切除,没有发生任何泄漏.
- 泄漏的独立预测因素包括缺少合闭合 (OR 7.0),免疫抑制 (OR 5.5) 和乳酸水平 (OR 1.4).
结论:
- 在可行的情况下,对于穿孔性胃潰瘍而言,首选的是合式闭合,而不是只用补丁的技术.
- 调查结果表明,由于该研究的回顾性,单一机构设计,需要谨慎.
更多相关视频
相关概念视频
Peptic Ulcer Disease V: Surgical Management and Nursing Care
194
Surgical management and nursing care are crucial in treating Peptic Ulcer Disease (PUD). Here is an organized and enhanced overview of the surgical interventions and the associated nursing care for PUD:
Surgical Interventions for Peptic Ulcer Disease
Surgical Interventions for Peptic Ulcer Disease
194
Peptic Ulcer Disease IV: Management
60
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
60
Esophageal Perforation-II: Clinical Manifestations and Management
36
Esophageal perforations manifest in various clinical forms, influenced by factors such as the perforation's cause and location (cervical, intrathoracic, or intra-abdominal), the extent of contamination, and potential injury to adjacent mediastinal structures. The timing between the perforation occurrence and treatment initiation also affects the clinical presentation.
Clinical Manifestations:
Clinical Manifestations:
36
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
364
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
364
Gastritis III: Clinical Manifestations and Management
124
The clinical manifestations of gastritis can vary depending on the cause and type of gastritis, but some common symptoms may include the following.
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...
124
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
327
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
327


